Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:42:14.114Z.
Calculation as of: 2026-10-06T15:42:14.114Z.
Quote observation: 2026-10-06T15:39:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
TuHURA Biosciences, Inc.
Market Cap
$121.63M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $121.63M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $123.17M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.38M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.21M | N/A |
| Genelux Corporation (GNLX)vs › | $116.57M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
